CN113730535A - Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN113730535A CN113730535A CN202111159285.XA CN202111159285A CN113730535A CN 113730535 A CN113730535 A CN 113730535A CN 202111159285 A CN202111159285 A CN 202111159285A CN 113730535 A CN113730535 A CN 113730535A
- Authority
- CN
- China
- Prior art keywords
- parts
- lung cancer
- chinese medicine
- treatment
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 140
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 107
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 107
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 107
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 37
- 235000006533 astragalus Nutrition 0.000 claims abstract description 31
- 241000132012 Atractylodes Species 0.000 claims abstract description 29
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 29
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 23
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 23
- 239000008187 granular material Substances 0.000 claims abstract description 19
- 241001061264 Astragalus Species 0.000 claims abstract description 17
- 210000004233 talus Anatomy 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 241000605372 Fritillaria Species 0.000 claims abstract description 7
- 230000012010 growth Effects 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- 238000009098 adjuvant therapy Methods 0.000 claims abstract description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract 8
- 241000234653 Cyperus Species 0.000 claims abstract 5
- 239000010072 ban-zhi-lian Substances 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 244000197580 Poria cocos Species 0.000 claims description 31
- 235000008599 Poria cocos Nutrition 0.000 claims description 31
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 27
- 241000915604 Scutellaria barbata Species 0.000 claims description 20
- 239000011812 mixed powder Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 8
- 229960004397 cyclophosphamide Drugs 0.000 claims description 8
- 241000202807 Glycyrrhiza Species 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 241000411851 herbal medicine Species 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003183 carcinogenic agent Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 5
- 229940010454 licorice Drugs 0.000 claims 5
- 241000407170 Curcuma Species 0.000 claims 4
- 240000002853 Nelumbo nucifera Species 0.000 claims 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 7
- 230000004614 tumor growth Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 2
- 244000164439 Curcuma angustifolia Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 51
- 235000013399 edible fruits Nutrition 0.000 description 25
- 240000009138 Curcuma zedoaria Species 0.000 description 23
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 23
- 210000000952 spleen Anatomy 0.000 description 23
- 244000303040 Glycyrrhiza glabra Species 0.000 description 22
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 22
- 235000019509 white turmeric Nutrition 0.000 description 22
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 20
- 235000011477 liquorice Nutrition 0.000 description 20
- 244000163122 Curcuma domestica Species 0.000 description 19
- 241000935235 Fritillaria meleagris Species 0.000 description 18
- 241000031023 Amana edulis Species 0.000 description 17
- 238000002512 chemotherapy Methods 0.000 description 17
- 241000045403 Astragalus propinquus Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 244000075634 Cyperus rotundus Species 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000766380 Iphigenia Species 0.000 description 6
- LWNOIQJAJMHMSM-UHFFFAOYSA-N Pariphyllin Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1OC2C(C(O)C(CO)O2)O)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O LWNOIQJAJMHMSM-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 235000016854 Cyperus rotundus Nutrition 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 244000150195 Cyperus longus Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 241001250596 Pleione Species 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 241000244987 Daiswa polyphylla Species 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 241000070780 Pleionea Species 0.000 description 2
- 241001038563 Pseudostellaria Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 241000234646 Cyperaceae Species 0.000 description 1
- 235000018109 Cyperus longus Nutrition 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 244000083724 Rhododendron simsii Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 235000005010 Scirpus paludosus Nutrition 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003088 amphibian venom Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000009462 endogenous apoptosis Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000035777 life prolongation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- -1 polysaccharide compounds Chemical class 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗肺癌的中药组合物及其煎煮剂和颗粒剂的制备方法及用途，它涉及中药的技术领域，具体涉及一种治疗肺癌的中药组合物及其煎煮剂和颗粒剂的制备方法及用途。本发明的目的是要解决现有中医组合物无法适宜大多数肺癌患者的问题。中药组合物由黄芪、太子参、生白术、茯苓、女贞子、浙贝母、山慈菇、干蟾皮、蚤休、半枝莲、莪术、香附和制成。制备方法：首先称取中药材，然后按照剂型为丸剂、胶囊剂、片剂、散剂、颗粒剂、口服液或煎煮剂制成治疗肺癌的中药制剂。在制备缩小或抑制肺癌瘤体生的药物中和在制备辅助治疗肺癌的药物中的用途。优点：能更好地抑制肺癌细胞的增殖，能够杀灭癌细胞，使病灶缩小或抑制肿瘤生长。A traditional Chinese medicine composition for the treatment of lung cancer, a preparation method and application of the decocting agent and granules, and the method and application thereof and use. The purpose of the present invention is to solve the problem that the existing traditional Chinese medicine composition cannot be suitable for most lung cancer patients. The traditional Chinese medicine composition is prepared from Astragalus, Taizishen, Atractylodes Rhizoma, Poria, Ligustrum lucidum, Fritillaria, Shanci Mushroom, dried toad skin, Fleas, Banzhilian, Curcuma Radix, Cyperus officinalis. Preparation method: firstly, Chinese medicinal materials are weighed, and then according to the dosage form, pills, capsules, tablets, powders, granules, oral liquids or decoctions are prepared into traditional Chinese medicine preparations for treating lung cancer. Use in the preparation of a medicament for reducing or inhibiting the growth of lung cancer tumors and in the preparation of a medicament for adjuvant treatment of lung cancer. Advantages: Can better inhibit the proliferation of lung cancer cells, can kill cancer cells, shrink the lesions or inhibit tumor growth.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating lung cancer and a preparation method and application of a traditional Chinese medicine preparation thereof.
Background
Malignant tumor is a disease seriously harming human health because of its high fatality rate and difficult cure, which have been health problems of global public nature that human beings generally pay attention to. Primary bronchogenic carcinoma, lung cancer for short, is one of the clinically common malignant tumors, the incidence of lung cancer is second worldwide and the mortality is first, so that the positive prevention and treatment of lung cancer is the focus of attention in China and all over the world. Currently, the main therapeutic approaches for lung cancer include surgery, radiation therapy, chemotherapy, and targeted therapy. In recent years, targeted therapy becomes a focus of treating lung cancer, and great progress is made, but the effect of targeted therapy is still not very ideal, and after radiotherapy and chemotherapy or operation, the life quality of patients is seriously reduced, so that many patients cannot adhere to the treatment, and the survival chance is lost.
In recent years, a multidisciplinary comprehensive treatment mode is gradually formed for treating lung cancer, and the traditional Chinese and western medicine combination therapy gradually shows unique advantages in treating the lung cancer, particularly middle and late stage lung cancer.
The traditional Chinese medicine means for treating lung cancer has the advantages of small side effect and convenience in implementation of individual treatment. However, the existing traditional Chinese medicine composition can only be used for targeted individual treatment and cannot be suitable for most lung cancer patients.
Disclosure of Invention
The invention aims to solve the problem that the traditional Chinese medicine composition cannot be suitable for most of lung cancer patients, and provides a traditional Chinese medicine composition for treating lung cancer and a preparation method and application of a traditional Chinese medicine preparation of the traditional Chinese medicine composition.
A traditional Chinese medicine composition for treating lung cancer is prepared from, by weight, 30-50 parts of astragalus membranaceus, 10-20 parts of radix pseudostellariae, 10-20 parts of raw bighead atractylodes rhizome, 10-20 parts of poria cocos, 20-40 parts of glossy privet fruit, 15-25 parts of thunberg fritillary bulb, 10-20 parts of Indian iphigenia bulb, 4-8 parts of dried toad skin, 10-20 parts of pariphyllin, 20-40 parts of barbed skullcap herb, 10-20 parts of curcuma zedoary, 7-13 parts of cyperus rotundus and 4-6 parts of liquorice.
A preparation method of a traditional Chinese medicine preparation for treating lung cancer comprises the following steps:
firstly, the traditional Chinese medicinal materials are weighed according to the parts by weight of the traditional Chinese medicinal composition for treating lung cancer, and then the traditional Chinese medicinal preparation for treating lung cancer is prepared into pills, capsules, tablets, powder, granules, oral liquid or decoction according to the dosage form.
The application of the traditional Chinese medicine composition for treating lung cancer in preparing medicines for reducing or inhibiting the growth of lung cancer tumor.
The application of the traditional Chinese medicine composition for treating lung cancer is the application in preparing a medicine for assisting in treating lung cancer.
The principle and the advantages of the invention are as follows:
the invention uses astragalus root and pseudostellaria root as main drugs. Astragalus is good at tonifying qi of both spleen and lung, is a key herb for strengthening body resistance, invigorating spleen and replenishing qi, has the characteristic of tonifying but not greasy, and is a common medicine for clinically invigorating qi, consolidating superficial resistance and strengthening body resistance. Pseudostellaria root, radix Pseudostellariae is good at tonifying qi and promoting the production of body fluid, and is commonly used for cough, asthma, anorexia, mental fatigue and hypodynamia caused by qi deficiency of spleen and lung. It has the obvious actions of tonifying qi and nourishing yin when combined with Huang Qi. Poria has effects of invigorating spleen, promoting diuresis, eliminating dampness, and strengthening spleen and eliminating dampness when used together with radix astragali and radix Pseudostellariae. The liquorice has the effects of tonifying qi, regulating the middle warmer and harmonizing the other drugs, has the effect of the four-monarch-drug decoction when being combined with the radix pseudostellariae, the tuckahoe and the bighead atractylodes rhizome, and has the effects of tonifying qi and strengthening the spleen, and the astragalus can improve the effects of the four-monarch-drug decoction on strengthening the spleen and tonifying qi and strengthen the function of protecting healthy energy. The glossy privet fruit is used for treating symptoms such as waist soreness, tinnitus, fever and the like caused by liver-kidney yin deficiency, is a good medicine for nourishing lung-kidney yin, and has the effect of relieving liver injury through modern pharmacological research. The medicines are used together to tonify the vital qi of the human body, strengthen the body resistance and nourish yin, adjust the balance of yin and yang, ensure the sufficient source of the biochemistry and play the efficacy of tonifying qi and nourishing yin together. Zhe Bei mu can resolve phlegm and dissipate nodulation, resolve both the tangible phlegm accumulated in the lung and the intangible phlegm, and resolve the accumulated cancer and swelling. The dried toad skin has the effects of clearing heat and removing toxicity, promoting diuresis and relieving flatulence, can treat carbuncle, tumors and the like, and has obvious efficacy on chronic and stubborn cancers. Pseudobulbus Cremastrae Seu pleiones can be used for treating carbuncle, swelling, sore, fistula, scrofula, and tuberculosis, and has effect in enhancing the disinfection and swelling of cutis Bufonis. The manyleaf paris rhizome has the effects of detoxifying, resisting cancer, reducing swelling and relieving pain, and is used for treating tumors. The barbed skullcap herb has the functions of clearing away heat and toxic material, dissipating stagnation and reducing swelling, and is widely applied to various anticancer prescriptions. Zedoary turmeric rhizome, rhizoma Curcumae has effects of removing blood stasis, activating qi-flowing, resolving food stagnation and relieving pain. Nutgrass galingale rhizome, rhizoma cyperi soothes liver and relieves depression, regulates qi and relieves epigastric distention. The medicines are used together to play the roles of reducing swelling, resolving masses, removing toxin and eliminating evil, and simultaneously, the functions of supporting vital qi and protecting the spleen and the stomach.
The astragalus, the radix pseudostellariae, the bighead atractylodes rhizome, the poria cocos, the glossy privet fruit, the thunberg fritillary bulb, the Indian iphigenia bulb, the cutis Bufonis, the paris rhizome, the barbed skullcap herb, the zedoary, the rhizoma cyperi and the liquorice are reasonably matched, and research and experiment results show that the synergistic effect is achieved between the astragalus, the radix pseudostellariae, the bighead atractylodes rhizome, the poria cocos, the glossy privet fruit, the paris rhizome, the barbed skullcap herb, the zedoary, the rhizoma cyperi and the liquorice, and the proliferation of lung cancer cells can be better inhibited.
Thirdly, the traditional Chinese medicine composition of the invention uses various medicines with anticancer effect, can kill cancer cells, reduce focus of infection or inhibit tumor growth, and is not inferior to chemotherapy medicines in the aspect of stabilizing focus of infection; and according to the treatment based on syndrome differentiation of the traditional Chinese medicine, the traditional Chinese medicine can be taken in combination with chemotherapy, and has the effects of strengthening body resistance and consolidating body resistance, improving the immunity of the organism, reducing the toxic and side effects of chemotherapy, simultaneously eliminating mass and removing food retention, assisting the chemotherapy and synergistically inhibiting tumors.
The traditional Chinese medicine composition has a fine formula and reasonable compatibility, can enhance the immunity of the body of a patient, obviously improve main clinical symptoms, improve the life quality of the patient, and enable the patient to actively fight against cancers, thereby achieving a better treatment effect.
The traditional Chinese medicine composition has small toxic and side effects, and has the effects of protecting spleen and stomach and preventing liver injury.
Sixth, the preparation method of the decoction and granule of the Chinese medicinal composition of the invention is simple in technological process, can improve the extraction rate of the active ingredient of raw materials, the active ingredient content of Chinese medicinal composition got is higher, the adjuvant therapy is better.
Seventhly, the traditional Chinese medicine composition is especially suitable for patients with advanced lung cancer who lose the chance of operation and radiotherapy, especially for patients who cannot receive chemotherapy for various reasons.
The traditional Chinese medicine composition disclosed by the invention can keep the balance of the internal environment of the body, regulate qi activity of internal organs, and enable yin and yang of internal organs to be mild, so that the immune system of the body is recovered, the growth of tumor cells is inhibited, and toxic and side effects caused by radiotherapy and chemotherapy are relieved, and the traditional Chinese medicine composition is also suitable for elderly patients with advanced lung cancer.
Detailed Description
The first embodiment is as follows: the embodiment is a traditional Chinese medicine composition for treating lung cancer, which is prepared from 30-50 parts by weight of astragalus, 10-20 parts by weight of radix pseudostellariae, 10-20 parts by weight of raw bighead atractylodes rhizome, 10-20 parts by weight of poria cocos, 20-40 parts by weight of glossy privet fruit, 15-25 parts by weight of thunberg fritillary bulb, 10-20 parts by weight of edible tulip, 4-8 parts by weight of cutis Bufonis, 10-20 parts by weight of paridis, 20-40 parts by weight of barbed skullcap herb, 10-20 parts by weight of curcuma zedoary, 7-13 parts by weight of xianghe and 4-6 parts by weight of liquorice.
Radix astragali is root of Astragalus membranaceus bge of Leguminosae, and has effects of invigorating qi, consolidating superficial resistance, expelling toxin, expelling pus, promoting urination, promoting granulation, etc. Can be used for treating deficiency of vital energy, asthenia, chronic diarrhea, proctoptosis, spontaneous perspiration, edema, uterine prolapse, albuminuria due to chronic nephritis, diabetes, and unhealed wound. The astragalus membranaceus is used as a traditional vital medicine for tonifying qi and can be used for treating various cancers such as lung cancer, and modern researches show that the astragalus membranaceus contains various anti-tumor active ingredients, and quercetin contained in the astragalus membranaceus can be used for obtaining drug-resistant cell PC9/GR apoptosis through Stat3/Mcl-1 and other ways, inhibiting tumor tissue VEGF and drug-resistant gene expression, and destroying Caspase-3 expression to inhibit proliferation and migration of lung cancer tumor cells; the kaempferol can inhibit the growth and proliferation of lung adenocarcinoma A549 cells, and can promote tumor cell apoptosis and increase radiation sensitivity by inhibiting the activation of a PI3K-Akt pathway, an ERK pathway and a mitochondrial apoptosis pathway.
Radix Pseudostellariae is dry root tuber of Pseudostellaria heterophylla of Caryophyllaceae. Has the effects of replenishing qi to invigorate the spleen, promoting the production of body fluid and moistening the lung. It is commonly used for spleen deficiency, fatigue, anorexia, weakness after illness, deficiency of qi and yin, spontaneous perspiration, thirst, dry lung and cough.
The white atractylodes rhizome is a perennial herb of the atractylodes of the Compositae, is a common and important bulk Chinese medicinal material, is distributed in Jiangsu, Zhejiang, Fujian, Jiangxi, Anhui, Sichuan, Hubei, Hunan and other places in China, is bitter, warm and pungent in nature and has the functions of tonifying spleen and strengthening stomach, eliminating dampness and promoting diuresis, stopping sweating and preventing abortion and the like. The rhizome of Atractylodes macrocephala contains volatile oil, the main components of the oil are atractylone, atractylol, atractylenolide, etc., and the drug has certain curative effect on ascites due to cirrhosis, primary liver cancer, Meniere's syndrome, chronic lumbago, acute enteritis, leukopenia, etc.
The poria cocos is dry sclerotia of the fungus poria cocos in the family of polyporaceae, is harvested in more than 7-9 months, is sweet and light in taste, is neutral in nature, enters heart, lung, spleen and kidney channels, promotes diuresis, excretes dampness, strengthens spleen, calms heart, and is used for treating edema oliguria, phlegm and fluid retention and dizziness and palpitation, spleen deficiency and poor appetite, loose stool and diarrhea, uneasiness, palpitation and insomnia. Research shows that the pachyman extracted from active tuckahoe can activate macrophage and T cell to induce TNF-alpha and IL-2, regulate body's immunity and strengthen antitumor capacity.
Fructus Ligustri Lucidi is fruit of Ligustrum lucidum belonging to Oleaceae. Picking fruits in winter, removing branches and leaves, and drying in the sun, or slightly smoking the fruits, and drying in the sun; or scalding in hot water and drying in the sun. The glossy privet fruit is neutral in nature, sweet and bitter in taste, enters liver and kidney channels, and has the effects of nourishing yin, prolonging life, tonifying liver and kidney, clearing heat, improving eyesight, blackening hair and beard and the like. It is often used to treat dizziness, tinnitus, blurred vision, soreness of the waist and knees, internal heat, and premature gray hair. Modern pharmacology indicates that the glossy privet fruit has the function of resisting liver injury.
Zhejiang fritillaria bulb, perennial herb. Has the functions of clearing away heat, eliminating phlegm, dispersing pathogen accumulation and detoxicating. Can be used for treating cough due to wind-heat evil, lung abscess, sore throat, scrofula, sore, ulcer, and toxic swelling.
Pseudobulbus Cremastrae Seu pleiones is dry pseudobulb of Rhododendron simsii, Pleionea or Pleionea yunnanensis of Orchidaceae, collected in summer and autumn. Pseudobulbus Cremastrae Seu pleiones is sweet and slightly pungent in flavor, and is cool in nature. Has the effects of clearing away heat and toxic materials, eliminating carbuncle, and resolving hard mass, and can be used for treating carbuncle, furuncle, scrofula, subcutaneous nodule, snake and insect bite, and limping. Modern pharmacological research finds that polysaccharide compounds contained in the edible tulip have certain proliferation inhibiting effect on tumor cells.
The dried toad skin mainly contains toad venom, has strong toxin-vanquishing and anticancer effects, and is an important anticancer drug. Has effects in increasing activity rate of mouse spleen hemolytic plaque forming cell (PEC), promoting macrophage function, increasing lysozyme concentration, enhancing immunity and circulatory system, and treating esophageal cancer, hepatocarcinoma, lung cancer, nephritis, diphtheria, and epidemic costal adenitis.
Rhizoma paridis is the rhizome of Paris polyphylla Smith, Paris polyphylla Smith and several plants of the same genus of Liliaceae. Paris root, rhizoma paridis, bitter and pungent in flavor, cold and toxic, enters heart and liver meridians to clear away heat and toxic materials, relieve asthma and cough, extinguish wind and relieve convulsion. It is indicated for abscess, furuncle, scrofula, sore throat, chronic tracheitis, infantile convulsions and convulsions, snake and insect bite. Can protect the liver and kidney functions of the organism and has better anticancer effect.
Scutellaria barbata is a perennial herb of Scutellaria of Labiatae. The herba Scutellariae Barbatae has effects in clearing away heat and toxic materials, promoting blood circulation, dispelling blood stasis, relieving swelling and pain, and resisting cancer. Is cold in nature and sour in taste, and the whole herb contains various vitamins, trace elements, amino acids and other components. Has the effects of cooling blood, removing toxic substances, removing blood stasis, relieving pain, relieving swelling, clearing heat and promoting diuresis.
The curcuma zedoary is a perennial herb of curcuma of Zingiberaceae, the rhizome is called as the curcuma zedoary, is used for medicine, and mainly treats stagnation of qi and blood, heart and abdomen distending pain, abdominal mass, accumulation, indigestion, blood stasis amenorrhea and traumatic injury pain of women. Studies show that the curcuma zedoaria can inhibit a JAK-STAT signal channel to play an anticancer role.
Cyperus rotundus, named as Chinese medicine. Is dried rhizome of Cyperus rotundus L of Cyperaceae. Plucked in autumn, singed to remove hair, boiled in boiling water or dried in the sun after steaming, or singed and dried in the sun directly. Pungent, slightly bitter, slightly sweet, neutral in nature, entering liver, spleen and triple energizer meridians, and has effects of dispersing stagnated liver qi for relieving qi stagnation, regulating qi-flowing for relieving epigastric distention, regulating menstruation and relieving pain. Can be used for treating stagnation of qi due to depression of the liver, distending pain in chest and hypochondrium, hernia pain, breast pain, stagnation of qi in spleen and stomach, abdominal distention, fullness and pain, menoxenia, amenorrhea, and dysmenorrhea. The volatile oil of rhizoma cyperi can strongly induce apoptosis to generate the effect of resisting lung cancer by activating endogenous apoptosis channels.
Licorice root, a perennial herb of Glycyrrhiza of Leguminosae, has strong root and rhizome, and is a tonifying Chinese herbal medicine. The medicinal parts are roots and rhizomes, and the medicinal parts are light in smell and sweet and special in taste. The functions are mainly used for clearing away heat and toxic material, eliminating phlegm and relieving cough. Licorice root is used for heart-qi deficiency, palpitation, intermittent pulse, deficiency of spleen-qi and stomach-qi, lassitude, fatigue, carbuncle, ulcer, sore throat, asthma, cough, stomach ache, abdominal pain, and acute pain of gastrocnemius. The hypochlorous acid contained in Glycyrrhrizae radix can block carcinogen from inducing tumor growth.
The second embodiment is as follows: the present embodiment differs from the first embodiment in that: the traditional Chinese medicine composition for treating lung cancer is prepared from 30 parts by weight of astragalus membranaceus, 10 parts by weight of radix pseudostellariae, 10 parts by weight of raw bighead atractylodes rhizome, 10 parts by weight of poria cocos, 20 parts by weight of glossy privet fruit, 15 parts by weight of thunberg fritillary bulb, 10 parts by weight of edible tulip, 5 parts by weight of dried toad skin, 10 parts by weight of paris rhizome, 20 parts by weight of barbed skullcap herb, 10 parts by weight of curcuma zedoary, 8 parts by weight of rhizoma cyperi and 4 parts by weight of liquorice. The rest is the same as the first embodiment.
The third concrete implementation mode: the present embodiment differs from the first embodiment in that: the traditional Chinese medicine composition for treating lung cancer is prepared from 40 parts by weight of astragalus membranaceus, 15 parts by weight of radix pseudostellariae, 15 parts by weight of raw bighead atractylodes rhizome, 15 parts by weight of poria cocos, 30 parts by weight of glossy privet fruit, 20 parts by weight of thunberg fritillary bulb, 15 parts by weight of edible tulip, 6 parts by weight of dried toad skin, 15 parts by weight of paris rhizome, 30 parts by weight of barbed skullcap herb, 15 parts by weight of curcuma zedoary, 10 parts by weight of rhizoma cyperi and 5 parts by weight of liquorice. The rest is the same as the first embodiment.
The fourth concrete implementation mode: the present embodiment differs from the first embodiment in that: the traditional Chinese medicine composition for treating lung cancer is prepared from 50 parts by weight of astragalus membranaceus, 20 parts by weight of radix pseudostellariae, 20 parts by weight of raw bighead atractylodes rhizome, 20 parts by weight of poria cocos, 40 parts by weight of glossy privet fruit, 25 parts by weight of thunberg fritillary bulb, 20 parts by weight of edible tulip, 8 parts by weight of cutis Bufonis, 20 parts by weight of pariphyllin, 40 parts by weight of barbed skullcap herb, 20 parts by weight of curcuma zedoary, 11 parts by weight of rhizoma cyperi and 6 parts by weight of liquorice. The rest is the same as the first embodiment.
The fifth concrete implementation mode: the embodiment is a preparation method of a traditional Chinese medicine preparation for treating lung cancer, which is specifically prepared by the following steps:
firstly, weighing the traditional Chinese medicinal materials according to the parts by weight of the traditional Chinese medicinal composition for treating lung cancer of any one of claims 1 to 4, and then preparing the traditional Chinese medicinal preparation for treating lung cancer by taking the traditional Chinese medicinal materials as pills, capsules, tablets, powder, granules, oral liquid or decoction according to the dosage forms.
The sixth specific implementation mode: the present embodiment is different from the fifth embodiment in that: the decoction is prepared by the following steps:
firstly, weighing: weighing traditional Chinese medicinal materials according to the weight parts of 30-50 parts of astragalus membranaceus, 10-20 parts of radix pseudostellariae, 10-20 parts of raw bighead atractylodes rhizome, 10-20 parts of poria cocos, 20-40 parts of glossy privet fruit, 15-25 parts of thunberg fritillary bulb, 10-20 parts of edible tulip, 4-8 parts of dried toad skin, 10-20 parts of manyleaf paris rhizome, 20-40 parts of sculellaria barbata, 10-20 parts of curcuma zedoary, 7-13 parts of cyperus rotundus and 4-6 parts of liquorice;
secondly, adding the Chinese medicinal materials weighed in the step one into 1000 parts of water, decocting until the rest amount of decoction with the volume of 300 parts of water is obtained, and subpackaging 150mL of each part to obtain the Chinese medicinal composition decoction for treating the lung cancer.
The rest is the same as the fifth embodiment.
The usage and dosage are as follows: the medicine is taken warmly, 1 part each time, twice a day, 1 time in the morning and at night, and 7 days are taken as a treatment course.
The seventh embodiment: the present embodiment differs from the sixth embodiment in that: in the first step, traditional Chinese medicinal materials are weighed according to the weight parts of 30 parts of astragalus, 10 parts of radix pseudostellariae, 10 parts of raw bighead atractylodes rhizome, 10 parts of poria cocos, 20 parts of glossy privet fruit, 15 parts of thunberg fritillary bulb, 10 parts of Indian iphigenia bulb, 5 parts of dried toad skin, 10 parts of pariphyllin, 20 parts of barbed skullcap herb, 10 parts of curcuma zedoary, 8 parts of rhizoma cyperi and 4 parts of liquorice. The rest is the same as the sixth embodiment.
The specific implementation mode is eight: the present embodiment differs from the sixth embodiment in that: in the first step, traditional Chinese medicinal materials are weighed according to the weight parts of 40 parts of astragalus mongholicus, 15 parts of radix pseudostellariae, 15 parts of raw bighead atractylodes rhizome, 15 parts of poria cocos, 30 parts of glossy privet fruit, 20 parts of thunberg fritillary bulb, 15 parts of edible tulip, 6 parts of dried toad skin, 15 parts of paris rhizome, 30 parts of barbed skullcap herb, 15 parts of curcuma zedoary, 10 parts of rhizoma cyperi and 5 parts of liquorice. The rest is the same as the embodiment eight.
The specific implementation method nine: the present embodiment differs from the sixth embodiment in that: in the first step, traditional Chinese medicinal materials are weighed according to the weight parts of 50 parts of astragalus mongholicus, 20 parts of radix pseudostellariae, 20 parts of raw bighead atractylodes rhizome, 20 parts of poria cocos, 40 parts of glossy privet fruit, 25 parts of thunberg fritillary bulb, 20 parts of edible tulip, 8 parts of dried toad skin, 20 parts of pariphyllin, 40 parts of barbed skullcap herb, 20 parts of curcuma zedoary, 11 parts of rhizoma cyperi and 6 parts of liquorice. The rest is the same as in the ninth embodiment.
The detailed implementation mode is ten: the present embodiment is different from the fifth embodiment in that: the decoction is prepared by the following steps:
firstly, weighing: weighing traditional Chinese medicinal materials according to the weight parts of 30-50 parts of astragalus membranaceus, 10-20 parts of radix pseudostellariae, 10-20 parts of raw bighead atractylodes rhizome, 10-20 parts of poria cocos, 20-40 parts of glossy privet fruit, 15-25 parts of thunberg fritillary bulb, 10-20 parts of edible tulip, 4-8 parts of dried toad skin, 10-20 parts of manyleaf paris rhizome, 20-40 parts of sculellaria barbata, 10-20 parts of curcuma zedoary, 7-13 parts of cyperus rotundus and 4-6 parts of liquorice;
secondly, crushing: cutting the radix pseudostellariae and the sculellaria barbata weighed in the step one into sections to obtain radix pseudostellariae sections and sculellaria barbata sections; ② mixing and crushing the astragalus, the raw white atractylodes rhizome, the paris rhizome, the zedoary, the rhizoma cyperi, the thunberg fritillary bulb, the glossy privet fruit and the liquorice which are weighed in the first step and the heterophylly falsestarwort root section and the barbed skullcap herb section which are obtained in the second step to obtain mixed powder A; cutting the poria cocos, the edible tulip and the dried toad skin weighed in the step one into pieces to obtain poria cocos pieces, edible tulip pieces and dried toad skin pieces, and mixing and crushing the poria cocos pieces, the edible tulip pieces and the dried toad skin pieces to obtain mixed powder B; mixing the mixed powder A obtained in the second step with the mixed powder B obtained in the second step to obtain mixed powder of the traditional Chinese medicinal materials;
thirdly, extraction: soaking the mixed powder of the traditional Chinese medicinal materials obtained in the step two in water for 20-40 min, and then extracting for 3-6 h at the temperature of 60 ℃ to obtain a traditional Chinese medicine extracting solution;
fourthly, concentration: concentrating the traditional Chinese medicine extracting solution obtained in the third step at the temperature of 50 ℃ to obtain clear paste, wherein the relative density of the clear paste is 1.10-1.15;
and V, granulating: adding auxiliary materials into the clear paste obtained in the fourth step, uniformly mixing, granulating, drying, and subpackaging according to 115.5g of equivalent products of the Chinese medicinal materials weighed in the first step to obtain the Chinese medicinal composition granules for treating lung cancer; the mass ratio of the auxiliary materials to the clear paste obtained in the fourth step is (1-1.5): 1; the auxiliary materials are one or a mixture of more of dextrin, sugar powder, polyvidone, polyethylene glycol and xylitol.
The rest is the same as the fifth embodiment.
The usage and dosage are as follows: is taken with warm water 1 part each time, twice a day, 1 time in the morning and evening, and 7 days is a treatment course.
The concrete implementation mode eleven: the present embodiment is different from the fifth embodiment in that: in the first step, traditional Chinese medicinal materials are weighed according to the weight parts of 30 parts of astragalus, 10 parts of radix pseudostellariae, 10 parts of raw bighead atractylodes rhizome, 10 parts of poria cocos, 20 parts of glossy privet fruit, 15 parts of thunberg fritillary bulb, 10 parts of Indian iphigenia bulb, 5 parts of dried toad skin, 10 parts of pariphyllin, 20 parts of barbed skullcap herb, 10 parts of curcuma zedoary, 8 parts of rhizoma cyperi and 4 parts of liquorice. The rest is the same as the embodiment.
The specific implementation mode twelve: the present embodiment is different from the fifth embodiment in that: in the first step, traditional Chinese medicinal materials are weighed according to the weight parts of 40 parts of astragalus mongholicus, 15 parts of radix pseudostellariae, 15 parts of raw bighead atractylodes rhizome, 15 parts of poria cocos, 30 parts of glossy privet fruit, 20 parts of thunberg fritillary bulb, 15 parts of edible tulip, 6 parts of dried toad skin, 15 parts of paris rhizome, 30 parts of barbed skullcap herb, 15 parts of curcuma zedoary, 10 parts of rhizoma cyperi and 5 parts of liquorice. The rest is the same as the embodiment.
The specific implementation mode is thirteen: the present embodiment is different from the fifth embodiment in that: in the first step, traditional Chinese medicinal materials are weighed according to the weight parts of 50 parts of astragalus mongholicus, 20 parts of radix pseudostellariae, 20 parts of raw bighead atractylodes rhizome, 20 parts of poria cocos, 40 parts of glossy privet fruit, 25 parts of thunberg fritillary bulb, 20 parts of edible tulip, 8 parts of dried toad skin, 20 parts of pariphyllin, 40 parts of barbed skullcap herb, 20 parts of curcuma zedoary, 11 parts of rhizoma cyperi and 6 parts of liquorice. The rest is the same as the embodiment.
The specific implementation mode is fourteen: the embodiment is an application of a traditional Chinese medicine composition for treating lung cancer, and the application is the application in preparing a medicine for reducing or inhibiting the growth of lung cancer tumor.
The concrete implementation mode is fifteen: the embodiment is application of a traditional Chinese medicine composition for treating lung cancer, and application of the traditional Chinese medicine composition in preparing a medicine for assisting in treating lung cancer.
The specific implementation mode is sixteen: the present embodiment is different from the fifteenth embodiment in that: the traditional Chinese medicine composition for treating lung cancer assists the application of cyclophosphamide in preparing the medicine for treating lung cancer. The rest is the same as the embodiment fifteen.
The invention is not limited to the above embodiments, and one or a combination of several embodiments may also achieve the object of the invention.
The following tests are adopted to verify the effect of the invention:
example 1: a preparation method of a traditional Chinese medicine composition decoction for treating lung cancer comprises the following steps:
firstly, weighing: weighing 40g of astragalus, 15g of radix pseudostellariae, 15g of raw bighead atractylodes rhizome, 15g of poria cocos, 30g of glossy privet fruit, 20g of thunberg fritillary bulb, 15g of Indian iphigenia bulb, 6g of dried toad skin, 15g of manyleaf paris rhizome, 30g of barbed skullcap herb, 15g of curcuma zedoary, 10g of nutgrass galingale rhizome and 5g of liquorice;
secondly, adding the traditional Chinese medicinal materials weighed in the step one into 1000mL of water, decocting until the residual decoction with the same volume of 300mL of water is obtained, and subpackaging 150mL of each decoction to obtain the traditional Chinese medicine composition decoction for treating lung cancer.
Example 2: a preparation method of a traditional Chinese medicine composition granule for treating lung cancer comprises the following steps:
firstly, weighing: weighing 40g of astragalus, 15g of radix pseudostellariae, 15g of raw bighead atractylodes rhizome, 15g of poria cocos, 30g of glossy privet fruit, 20g of thunberg fritillary bulb, 15g of Indian iphigenia bulb, 6g of dried toad skin, 15g of manyleaf paris rhizome, 30g of barbed skullcap herb, 15g of curcuma zedoary, 10g of nutgrass galingale rhizome and 5g of liquorice;
secondly, crushing: cutting the radix pseudostellariae and the sculellaria barbata weighed in the step one into sections to obtain radix pseudostellariae sections and sculellaria barbata sections; ② mixing and crushing the astragalus, the raw white atractylodes rhizome, the paris rhizome, the zedoary, the rhizoma cyperi, the thunberg fritillary bulb, the glossy privet fruit and the liquorice which are weighed in the first step and the heterophylly falsestarwort root section and the barbed skullcap herb section which are obtained in the second step to obtain mixed powder A; cutting the poria cocos, the edible tulip and the dried toad skin weighed in the step one into pieces to obtain poria cocos pieces, edible tulip pieces and dried toad skin pieces, and mixing and crushing the poria cocos pieces, the edible tulip pieces and the dried toad skin pieces to obtain mixed powder B; mixing the mixed powder A obtained in the second step with the mixed powder B obtained in the second step to obtain mixed powder of the traditional Chinese medicinal materials;
thirdly, extraction: soaking the mixed powder of the traditional Chinese medicinal materials obtained in the step two in water for 30min, and then extracting at 60 ℃ for 5h to obtain a traditional Chinese medicine extracting solution;
fourthly, concentration: concentrating the Chinese medicinal extract obtained in the third step at 50 ℃ to obtain clear paste, wherein the relative density of the clear paste is 1.13;
and V, granulating: adding dextrin into the clear paste obtained in the fourth step, uniformly mixing, granulating, drying, uniformly dividing into 2 parts, and packaging to obtain the traditional Chinese medicine composition granules for treating lung cancer; the mass ratio of the dextrin to the clear paste obtained in the fourth step is 1.2: 1.
Example 3: an application of a Chinese medicinal composition for treating lung cancer in preparing medicines for reducing or inhibiting tumor growth of lung cancer; when the traditional Chinese medicine composition for treating lung cancer is the traditional Chinese medicine composition decoction for treating lung cancer obtained in example 1, the dosage of the traditional Chinese medicine composition decoction for treating lung cancer is as follows: warm taking 1 part each time, twice a day, 1 time in the morning and evening, and 7 days as a treatment course; when the traditional Chinese medicine composition for treating lung cancer is the traditional Chinese medicine composition granule for treating lung cancer obtained in example 2, the dosage of the traditional Chinese medicine composition granule for treating lung cancer is as follows: is taken with warm water 1 part each time, twice a day, 1 time in the morning and at night, and 7 days as a treatment course;
example 4: an application of a traditional Chinese medicine composition for treating lung cancer, which is used for assisting cyclophosphamide in preparing a medicine for treating lung cancer; the cyclophosphamide is cyclophosphamide tablets; cyclophosphamide (C0768-1G) is used in an adult: 2 mg/kg-4 mg/kg per day for oral administration; the application is continued for 10 to 14 days, and the rest is repeated for 1 to 2 weeks. The common dosage for children is as follows: orally taking 2 mg/kg-6 mg/kg every day for 10-14 days, and repeating the rest for 1-2 weeks; when the traditional Chinese medicine composition for treating lung cancer is the traditional Chinese medicine composition decoction for treating lung cancer obtained in example 1, the dosage of the traditional Chinese medicine composition decoction for treating lung cancer is as follows: warm taking 1 part each time, twice a day, 1 time in the morning and evening; 7 days is a treatment course; when the traditional Chinese medicine composition for treating lung cancer is the traditional Chinese medicine composition granule for treating lung cancer obtained in example 2, the dosage of the traditional Chinese medicine composition granule for treating lung cancer is as follows: is taken with warm water 1 part each time, twice a day, 1 time in the morning and at night, and 7 days is a treatment course.
(1) Animal experiments:
1. preparation of animal model
Tumor cells are inoculated to tumor-bearing mice for experiments according to a conventional method, tumor strains which are automatically passaged for 7 days in a laboratory are taken, and milky ascites which grows well is extracted under the aseptic condition. Solid tumor S180Diluting with normal saline to 5 × 106one/mL, 0.2 mL/mouse right underarm subcutaneous inoculation.
2. Grouping and administration of drugs
The main reagents are as follows: a traditional Chinese medicine composition, namely the traditional Chinese medicine composition granules for treating lung cancer prepared in the embodiment 2; ② Cyclophosphamide (CTX), No. C0768-1G, MTT product of Sigma company. ③ TNF-alpha kit: product of bondine biomedical corporation.
Divided into five groups of 10. A physiological saline solution group: and (5) performing intragastric lavage by 0.2 mL. ② CTX group: and (5) performing intragastric administration at 15 mg/kg. ③ Chinese medicine small dose group: 7.8g/kg of the mixture is used for intragastric administration. Fourthly, the traditional Chinese medicine large dose group: and (3) performing intragastric administration at the concentration of 23.4 g/kg. Middle and small + CTX group: the CTX is perfused with 15mg/kg, and the traditional Chinese medicine is perfused with 7.8 g/kg; each group was administered 1 time per day for 10 consecutive days.
3. For mouse S180Tumor suppression assay
Stopping taking the medicine the next day, killing the mice by removing the neck, stripping tumor masses, weighing the tumor weight, and calculating the tumor inhibition rate according to the following formula 1, wherein the result is shown in
Table 1.
TABLE 1
The statistical methods of the experiment all use t test.
4. To S180Effect of immune organ weight in mice
The next day of drug withdrawal, mice were sacrificed, the weights were weighed, the spleen and thymus were taken under aseptic conditions, the wet weights were weighed with a torsion balance, and the spleen index and thymus index were calculated, and the results are shown in table 2.
TABLE 2
Note: statistical methods all use t test:*P<0.05.**P<0.01. comparing with the normal saline group;△P<0.05.△△P<0.01. compared to the CTX group.
5. To S180Effect of lymphocyte transformation efficiency in mice
MTT colorimetric method is used. Stimulation index SI ═ mean OD value in experimental group/mean OD value in control group. The results are shown in Table 3.
TABLE 3
Note: statistical methods all use t test:*P<0.05.**P<0.01. comparing with the normal saline group;△P<0.05.△△P<0.01. compared to the CTX group.
6. To S180Effect of mouse Natural killer cell (NK cell) Activity
Measured by colorimetry. The killing rate%.
TABLE 4
Note: statistical methods all use t test:*P<0.05.**P<0.01. comparing with the normal saline group;△P<0.05.△△P<0.01. compared to the CTX group.
7. To S180Effect of mouse Tumor Necrosis Factor (TNF) content
The TNF content was measured according to the method described in the TNF-alpha kit of Beijing Bangding biomedical corporation, and the results are shown in Table 5.
TABLE 5
Note: statistical methods all use t test:*P<0.05.**P<0.01. comparing with the normal saline group;△P<0.05.△△P<0.01. compared to the CTX group.
8. The statistical method comprises the following steps: and (5) carrying out the homogeneity test of the variances, wherein the variances are tested by using t at the same time, and the variances are tested by using t' at different times.
Conclusion of animal experiments:
experiments on solid tumor-bearing mice show that the tumor inhibition rate of the traditional Chinese medicine composition on the tumor-bearing mice is more than 30%, and the traditional Chinese medicine composition has a trend of obviously enhancing the curative effect tumor inhibition rate when being used together with chemotherapeutic drugs. The determination of the lymphocyte transformation rate, the natural killer cell (NK cell) activity, the Tumor Necrosis Factor (TNF) content, the thymus index and the spleen index of the tumor-bearing mice shows that the traditional Chinese medicine composition can obviously improve the lymph transformation rate of the tumor-bearing mice, enhance the NK cell activity, improve the TNF content and increase the thymus index and the spleen index, thereby showing that the invention can improve the immunity function of organisms. The experiment also shows that the traditional Chinese medicine composition disclosed by the invention can antagonize the immunosuppression state caused by chemotherapeutic drugs, and can restore the normal immune function of tumor-bearing mice.
1. The traditional Chinese medicine composition has obvious effects of resisting stheniaBody tumor action on S180The inhibition rate of the growth of the tumor mass of the mouse is about 43 percent (P)<0.01), and the Xiaobu granules are combined with cyclophosphamide, so that the trend of obviously improving the tumor inhibition rate is achieved, and the tumor inhibition rate reaches 51.35 percent (P)<0.01)。
2. The traditional Chinese medicine composition has no obvious tumor inhibition effect on ascites type tumors and has no obvious effect on ascites type H of mouse liver cancer22Has no significant effect on life prolongation rate (P)>0.05) but has a tendency to significantly prolong survival when used in combination with the chemotherapeutic agent CTX.
3. The traditional Chinese medicine composition can obviously improve S180Mouse thymus index, spleen index.
4. The traditional Chinese medicine composition has the function of enhancing S180Function of mouse lymphocyte transformation rate.
5. The traditional Chinese medicine composition can improve S180Mouse NK cell activity.
6. The traditional Chinese medicine composition can promote the growth of S180The mouse TNF content is increased.
7. The traditional Chinese medicine composition can improve S180The immune function of the mouse body can also antagonize the reduction of the immune function caused by CTX.
(2) Clinical efficacy study:
1. research method
In the research, 96 patients with advanced lung cancer are selected from clinical tests, and are randomly divided into 49 patients in a treatment group (a tonifying granule group) and 47 patients in a control group (a chemotherapy group) for clinical observation (traditional Chinese medicine + CTX is added); (the usage amount of the medicine in the treatment group is given, and the treatment time is given) and the peripheral blood T cell subgroup, NK cell activity and IL-2 activity level of the patients before and after treatment in the treatment group are simultaneously detected and compared with a normal control group. The treatment group is superior to the control group (P) in improving clinical symptoms and improving quality of life<0.05); comparison of post-treatment versus pre-treatment, CD, for treatment groups+ 4T cells and CD+ 4/CD+ 8The value is obviously increased (P)<0.01),CD+ 8Significant decrease in T cells (P)<0.01), the NK cell activity and the IL-2 activity level are obviously improved (P)<0.01)。
2. Reasonably collecting, screening and grouping medical records
The cases originated from the subsidiary college of Heilongjiang university of traditional Chinese medicine and the third Hospital of Harbin medical university, in total 96 cases, wherein IIIBStage 79, stage IV 17, youngest 42 years, youngest 75 years, average 58.8 years. Treatment group 49, 40 men and 9 women; the control group 47, the male 38 and the female 9 have no obvious difference in sex, age, tumor size, TNM stage, Karnofsky score and the like, and have comparability. In addition, 15 normal healthy control groups, 12 men and 3 women, with an average age of 59 years were set.
30 cases in the affiliated college of the university of traditional Chinese medicine of Heilongjiang are shown in Table 6.
TABLE 6
3. Observation index
Change of tumor size: after a treatment period, the chest radiograph is reviewed, and the size of the mass is measured and compared with that before treatment.
② changes of main clinical symptoms: the change of cough, dyspnea and chest pain before and after treatment was observed.
And thirdly, the quality of life changes: scoring according to Karnofsky physical condition scoring standard, and comparing before and after treatment.
Fourthly, CD is measured by adopting a monoclonal antibody sensitized erythrocyte rosette method+ 4、CD+ 8Horizontal and CD+ 4/CD+ 8A ratio.
Fifth, statistical treatment: chi-square test and t-test were used.
4. Criteria for efficacy assessment
The evaluation standard of objective curative effect of WHO solid tumor is adopted, the curative effect is divided into four grades according to different changes of the size of the treated tumor, and the judgment standards of all grades are shown in a table 7.
TABLE 7
The effective rate is as follows: is CR rate + PR rate
The stability ratio: is CR rate + PR rate + NC rate
5. Statistical treatment
The following steps
1) Changes in tumor size as an indicator of recent objective efficacy. The results are shown in Table 8.
TABLE 8
*P>0.05
2) Changes in major clinical symptoms, see table 9.
TABLE 9
3) Quality of life change, see table 10.
Watch 10
4) The effect on the immune function of the body is shown in table 11.
TABLE 11
Comparison with Normal group before treatment*P<0.05; comparison of post-treatment vs pre-treatment Δ P for treatment groups<0.01; comparison of treated groups with Normal groups#P<0.05,##P<0.01
② conclusion
Through clinical observation, the traditional Chinese medicine composition can inhibit the tumor growth of patients with advanced lung cancer and stabilize the focus; the main clinical symptoms of patients with advanced lung cancer are improved, and the effect is better than that of patients only using chemotherapy drugs; improve the life quality and the immunologic function of the patients with the advanced lung cancer. Is an anti-tumor Chinese herbal medicine compound preparation which strengthens the body resistance and eliminates pathogenic factors simultaneously and is worthy of clinical popularization and deep research.
1. The traditional Chinese medicine composition can inhibit the tumor growth of patients with advanced lung cancer and stabilize the focus. The effective rate is 16.53%, the lesion stabilizing rate is 93.88%, and the effect is not obviously different from that of a chemotherapy control group (P is more than 0.05).
2. The traditional Chinese medicine composition can improve the main clinical symptoms of patients with advanced lung cancer, and is superior to a chemotherapy control group (P < 0.05).
3. The traditional Chinese medicine composition can improve the life quality of patients with advanced lung cancer, and the Karnofsky score improvement rate of a treatment group is superior to that of a chemotherapy control group (P is less than 0.05).
4. The traditional Chinese medicine composition can enable patients with advanced lung cancer to have CD+ 4T cells and CD+ 4/CD+ 8The ratio is obviously increased (P)<0.01) making CD+ 8Significant decrease in T cells (P)<0.01), can improve NK cell activity (P) of patients with advanced lung cancer<0.01), can increase IL-2 activity level (P) of patients with advanced lung cancer<0.01), thereby being capable of improving the immune function of patients with advanced lung cancer.
5. The traditional Chinese medicine composition is an anti-tumor traditional Chinese medicine compound preparation which has the effects of strengthening body resistance and eliminating evil simultaneously and is worthy of clinical popularization and deep research.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111159285.XA CN113730535A (en) | 2021-09-30 | 2021-09-30 | Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111159285.XA CN113730535A (en) | 2021-09-30 | 2021-09-30 | Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113730535A true CN113730535A (en) | 2021-12-03 |
Family
ID=78725787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111159285.XA Pending CN113730535A (en) | 2021-09-30 | 2021-09-30 | Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113730535A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470137A (en) * | 2022-03-01 | 2022-05-13 | 湖南省中医药研究院 | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof |
| US20220152143A1 (en) * | 2020-11-17 | 2022-05-19 | The First Afiliated Hospital Of Guangzhou University Of Chinese Medicine | Strengthening and tumor eliminating traditional chinese medicine composition, its preparation method and application |
| CN116492423A (en) * | 2023-04-14 | 2023-07-28 | 上海市第十人民医院 | A kind of traditional Chinese medicine composition for preventing and treating lung cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1439418A (en) * | 2003-01-30 | 2003-09-03 | 成都利尔药业有限公司 | Auxiliary medicine for cancer and preparation thereof |
-
2021
- 2021-09-30 CN CN202111159285.XA patent/CN113730535A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1439418A (en) * | 2003-01-30 | 2003-09-03 | 成都利尔药业有限公司 | Auxiliary medicine for cancer and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 于佩雯;等: "四君子汤配伍清毒药治疗肺癌举隅", 《实用中西医结合临床》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220152143A1 (en) * | 2020-11-17 | 2022-05-19 | The First Afiliated Hospital Of Guangzhou University Of Chinese Medicine | Strengthening and tumor eliminating traditional chinese medicine composition, its preparation method and application |
| US11524044B2 (en) * | 2020-11-17 | 2022-12-13 | The First Afiliated Hospital Of Guangzhou University Of Chinese Medicine | Strengthening and tumor eliminating traditional Chinese medicine composition, its preparation method and application |
| CN114470137A (en) * | 2022-03-01 | 2022-05-13 | 湖南省中医药研究院 | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof |
| CN116492423A (en) * | 2023-04-14 | 2023-07-28 | 上海市第十人民医院 | A kind of traditional Chinese medicine composition for preventing and treating lung cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100586468C (en) | Chinese medicine for treating hepatitis B | |
| CN113730535A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition | |
| CN103585514B (en) | A kind of be used for the treatment of gastric cancer Chinese medicine composition, application and preparation | |
| CN103893722A (en) | Traditional Chinese medicinal composition for treating solar dermatitis and preparation method thereof | |
| CN103316249B (en) | Astragalus taxus chinensis capsule and preparing process thereof | |
| CN103007012B (en) | Traditional Chinese medicine composition for treating toothaches and preparation method thereof | |
| CN102247479A (en) | Antitumor strong medicine and preparation method thereof | |
| CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
| CN113209194B (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
| CN104800538A (en) | Traditional Chinese medicine for treating lung cancer | |
| CN104800459A (en) | Traditional Chinese medicine for treating stomach cancer | |
| CN102552541B (en) | Medicinal composition for preventing or treating breast cancer | |
| CN104825818A (en) | Traditional Chinese medicine for treating asthma | |
| CN104840773A (en) | Traditional Chinese medicine composition for treating vertebral artery type cervical spondylopathy and method for preparing same | |
| CN104940752A (en) | Chinese medicine preparation for treating vulva ulcer and preparing method thereof | |
| CN105106555A (en) | Traditional chinese medicine for treating gastric cancer | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN104922595A (en) | Traditional Chinese medicinal preparation for herpes zoster and preparation method thereof | |
| CN106474421B (en) | A traditional Chinese medicine composition for treating colorectal cancer and its application | |
| CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof | |
| CN104815177A (en) | Traditional Chinese medicine for treating asthma of children | |
| CN114533695A (en) | An oral Chinese medicinal composition for treating ankylosing spondylitis and its preparation method | |
| CN111437329A (en) | Formula of universal conditioning external composition | |
| CN104666468A (en) | Pharmaceutical composition for treating hyperthyroidism and scrofula | |
| CN104784608B (en) | Preparation method of medicine for improving toxic and side effects of tumor chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |